Future Therapies of Psoriasis


Atakan N.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.42, ss.56-59, 2008 (SCI İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42
  • Basım Tarihi: 2008
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Sayfa Sayıları: ss.56-59

Özet

For many years psoriasis was thought to be an epidermal disorder resulting from uncontrolled hyperproliferation of keratinocytes. After the discovery of T cell targeted immunosuppressive agents improving psoriasis, it has been considered as a T cell mediated autoimmune disease. Systemic agents including methotrexate, tretinoin, cyclosporin have been used to treat psoriasis for over 30 years. The understanding of psoriasis as a T-cell mediated disease has led to the development of biologic agents which target key molecules in the pathologic process. These new agents named biologicals appear to be safer than the agents in traditional therapies. Because they are so new and their long term safety is not established well; scientists are exploring several new therapeutic targets. Several new molecules such as angiogenesis inhibitors, immunomodulatory compounds, intracellular messenger targets, anti-inflammatory molecules, anti-integrins can be possible future treatment agent of psoriasis. (Turkderm 2008; 42 Suppl 2: 56-9)